Alena Vrbacká

Alena Vrbacká

Auto-generated profile, based on publicly available information

Alena Vrbacká

Research Unit for Rare Diseases, Department of Pediatrics and Metabolic Disorders, First Faculty of Medicine, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
VKVendula Havlíčková Karbanová
Vendula Havlíčková Karbanová
AVAlena Vrbacká
Alena Vrbacká
KHKateřina Hejzlarová
Kateřina Hejzlarová
HNHana Nůsková
Hana Nůsková
VSViktor Stránecký
Viktor Stránecký
JHJosef Houštěk
Josef Houštěk

1 July 2012 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
NKNikola Kovářová
Nikola Kovářová
AVAlena Vrbacká
Alena Vrbacká
PPPetr Pecina
Petr Pecina
VSViktor Stránecký
Viktor Stránecký
EPEwa Pronicka
Ewa Pronicka
JHJosef Houštěk
Josef Houštěk

1 January 2011 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
KHKateřina Hejzlarová
Kateřina Hejzlarová
MTMarkéta Tesařová
Markéta Tesařová
AVAlena Vrbacká
Alena Vrbacká
MVMarek Vrbacký
Marek Vrbacký
HHHana Hartmannová
Hana Hartmannová
JHJosef Houštěk
Josef Houštěk

10 April 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AVAlena Vrbacká
Alena Vrbacká
APAnna PřIstoupilová
Anna PřIstoupilová
KKKendrah O. Kidd
Kendrah O. Kidd
VJVáclav Janoušek
Václav Janoušek
MRMartin Radina
Martin Radina
SKStanislav Kmoch
Stanislav Kmoch
Key Points: Single-molecule real-time sequencing with the PacMUC1 script resolved exact MUC1 variable tandem repeat structure and full allelic variation. In 300 individuals, the protocol identified 215 distinct MUC1 tandem repeat alleles with 80 repeat units and nine frameshift mutation types. Probe extension assay identified 90% of families with frameshift mutations, detection of frameshifted mucin-1 aided genetically unresolved cases. Background: ADTKD- MUC1 is caused by frameshift mutations in the MUC1 gene, producing a frameshifted neoprotein (MUC1fs) toxic to kidney cells. The gene's variable number of tandem repeats (VNTR), with approximately 80% guanine/cytosine content, has made it largely inaccessible to standard short-read sequencing, leaving the reference sequence and natural variation poorly defined and complicating mutation detection. Methods: Using single-molecule real-time (SMRT) sequencing, we characterized MUC1 VNTR in 300 individuals, including 279 from 143 families suspected of having ADTKD- MUC1 , assessing VNTR length, repeat structure, and frameshift mutations. Results were compared with the Clinical Laboratory Improvement Amendments–approved probe-extension assay, detecting the prevalent 59dupC mutation, and with MUC1fs immunohistochemistry, which detects the pathogenic protein independent of the underlying genomic change. Results: We identified 215 unique VNTR alleles composed of 80 distinct repeat units, 46 (58%) of which were novel, and nine distinct frameshift mutations present on 52 mutated alleles. Overall, MUC1 frameshift mutations were identified in 71 of 143 families (50%) with suspected ADTKD- MUC1 , comprising 135 affected individuals (48%). The SMRT assay outperformed the probe-extension assay by identifying frameshift mutations in two families with previously inconclusive results and in eight additional families whose mutations were undetectable by the probe-extension design. When successful, SMRT assay showed 100% concordance with probe-extension assay at the family level and 98% at the individual level, with discordance attributable to allelic dropout inherent to both long-range PCR amplification and long-read sequencing. Analysis of the mutational spectrum confirmed 59dupC as the most prevalent mutation, affecting approximately 90% of families, while the other eight mutation types occurred at most twice. Conclusions: The SMRT assay outperformed the Clinical Laboratory Improvement Amendments-approved probe-extension assay by detecting essentially all VNTR-associated frameshift mutations. The probe-extension assay identified approximately 90% of affected families. MUC1fs immunohistochemistry added diagnostic value in genetically unresolved cases by detecting the pathogenic protein independent of the underlying mutation.

3 June 2026 in medRxiv
Verified
Preprint
Open access
PDF file
BPBernt Popp
Bernt Popp
HSHassan Saei
Hassan Saei
OTOmri Teltsh
Omri Teltsh
VJVáclav Janoušek
Václav Janoušek
APAnna PřIstoupilová
Anna PřIstoupilová
JHJan Peter Halbritter
Jan Peter Halbritter
Background: ADTKD- MUC1 is one of the major entities of ADTKD caused by frameshift variants in the MUC1 VNTR that standard short-read sequencing fails to detect. Existing 59dupC-targeted probe-extension assays do not allow for broad screening and cannot detect atypical non-dupC variants. Recently, VNtyper, a Kestrel-based genotyping pipeline with optional code-adVNTR cross-validation for MUC1 VNTR genotyping from short-read sequencing data allowed to circumvent this diagnostic limitation, but needed further development for easy access and rapid sample processing. Methods: We developed VNtyper 2, by refactoring VNtyper into a modular, production-grade tool with a companion web platform, VNtyper-Online ( https://vntyper.org ), for freely available browser-based analysis with short turnaround time and without local bioinformatics infrastructure. We validated VNtyper 2 on 400 simulated samples generated with MucOneUp and 142 clinical exomes with independently confirmed genotypes. Results: In simulation, VNtyper 2 detected the canonical 59dupC variant with 96% sensitivity and 100% specificity. Reference-standard validation on 142 samples yielded 90.6% sensitivity and 98.2% specificity overall, with cohort-dependent performance across the Twist Exome v2 French-German cohort (98% sensitivity, 87.5% specificity) and the KAPA HyperExome V2 (Roche) Czech-US cohort (79.4% sensitivity, 100% specificity). Screening of 3582 exomes and targeted panels from international CKD referral programmes identified 51 positive individuals, including 9 with atypical non-dupC frameshift variants that would have been missed by 59dupC-targeted probe-extension assays. In unselected CKD cohorts, a descriptive random-effects summary estimated a detection rate of 1.4% (95% CI 0.6 to 3.1%). Conclusions: VNtyper 2 and VNtyper-Online are open-source tools for MUC1 VNTR genotyping from short-read data and can support locally validated workflows when VNTR coverage is adequate. By improving accessibility and turnaround time, these tools democratize MUC1 diagnostics at global scale. For its integration into routine diagnostics, we propose an expert-informed two-pathway workflow developed through European ADTKD-Net consortium consensus.

Verified
Journal Article
Open access
PDF file
OPOndrej Ptacek
Ondrej Ptacek
ZMZdeněk Musil
Zdeněk Musil
GGGiulia Guarnieri
Giulia Guarnieri
AVAlena Vrbacká
Alena Vrbacká
PMPavla Moudrá
Pavla Moudrá
PZPetr Zach
Petr Zach
Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disorder; to date, there is no long-term effective treatment. Recently, a relationship has been discovered between the human intestinal microbiome and the pathogenesis of ALS, on which basis faecal microbiota transplantation (FMT) has been proposed as a potential treatment for ALS. In this review, we compare three existing case studies examining the effect of FMT on the course of ALS, highlighting differences in methodology and results. In two of the studies, a halt in the progression of ALS symptoms was observed following FMT, accompanied by improvement in patient health. However, in the third and largest study, no significant effect of FMT was observed. The possible explanation for this discrepancy may be the intentional depletion of intestinal microorganisms using antibiotics prior to FMT in the third study. Future studies and/or completion of the ongoing clinical studies will help clarify the therapeutic effectiveness of FMT in ALS patients.